NeuraMetrix Inc. gets listed on THE OCMX™

The OCMX™ is pleased to announce the listing of NeuraMetrix Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

SAN FRANCISCO, CA, October 26, 2020 /24-7PressRelease/ -- NeuraMetrix is a San Francisco based medtech company founded in 2013 in San Francisco by Swedish cybersecurity executives, Jan Samzelius and Christian Olsson. NeuraMetrix' mission is to support neurologists and psychiatrists with an accurate tool to diagnose and monitor and assess the efficacy of a particular treatment for various Neurological diseases and Psychiatric disorders.

NeuraMetrix is an accurate tool to diagnose and monitor and assess the efficacy of a particular treatment for various Neurological diseases and Psychiatric disorders. NeuraMetrix measures the rhythm with which we type on a keyboard to monitor the brain health of the individual patient every time the computer keyboard is used.

A neurologist can with NeuraMetrix monitor the effect of medication changes for an individual patient by accessing the patient's chart a few weeks later and determining if the changes had desired effect, no effect, or, at worst, adverse effects.

NeuraMetrix and its Scientific Advisors are confident that the technology will also enable early detection of neurodegenerative diseases and psychiatric disorders, making early intervention feasible. These diseases represent the largest challenge to the global healthcare system, making NeuraMetrix technology crucial for society.

The OCMX™ is pleased to announce the listing of NeuraMetrix Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on NeuraMetrix Inc. and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that NeuraMetrix Inc. exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

OPPORTUNITY HIGHLIGHTS

• No reliable biomarkers for continuous patient monitoring and diagnostics exist for these diseases. The market for monitoring of Neurological diseases and Psychiatric disorders has together been estimated to be at least $36 billion. The Company is currently seeing great demand in Psychiatry.

• The CE-marked product is market-ready for use in Europe. It was designated as a "Breakthrough Device" by the FDA in 2019 and should soon be ready for launch also in the US, most probably as a reimbursed product by Medicare and Medicaid.

• NeuraMetrix has already patient data from clinical trials, for up to 22 months, confirming the accuracy and great precision of this device.

• The first two US patent applications have recently been approved (Q2 2020).

MANAGEMENT TEAM

Jan Samzelius, Founder, CEO and CTO
Jan has specialized in quantitative methods for 40 years and has invented the typing cadence technology central to NeuraMetrix. He has been the CEO of six companies (most of them startups), in several cases improving profits dramatically and he holds a BSc in Economics from the Stockholm School of Economics (Sweden), and an MBA from Harvard Business School.

Christian Olsson, Co-Founder and VP of Marketing
Christian has extensive marketing, alliances and sales management experience with startups, including Co-Founder/VP Marketing of three software startups, VP/Director Business Development of two software startups and President of one software startup (turn around). Christian holds an MBA from Lund University (Sweden) and a Mechanical Engineering Degree from the Tycho Brahe Technical College (Sweden).

Oleg Salyakhov, VP of Engineering
Oleg is an accomplished Senior Software Engineer whose career includes working at a major game publisher and a major hardware vendor, prior to that he was the CTO at a major DRM vendor where he developed the only DRM to hold up for 430 days. Oleg holds a MS in Computer Science from Moscow Tech University.

Kenneth Forssell, Managing Director Nordics
Ken has 25+ years in management, operations and business development in pharma and medtech including VP & General Manager at GlaxoSmithKline and have had senior positions at several medtech startups. Ken holds an MSc in Pharmacy from University of Helsinki (Finland).

ABOUT THE OCMX™

The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: prosper@theocmx.com



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com